A Phase 3 study funded by Pfizer Inc. (NYSE:PFE) suggests that a nucleoside-modified messenger RNA influenza vaccine could offer stronger protection than traditional flu shots, marking a potential shift in how seasonal influenza is prevented.

Researchers reported that the experimental quadrivalent modRNA vaccine delivered higher efficacy against circulating flu strains, though it also produced more short-term reactions following vaccination.

The trial evaluated healthy adults ages 18 to 64 during the 2022–2023 flu season. In total, 18,476 volunteers were enrolled, with roughly half in each study arm.

Participants were randomly assigned to receive either the investigational modRNA vaccine or a licensed inactivated quadrivalent influenza vaccine that served as the control.

Also Read: Moderna’s mRNA Flu Vaccine Outperforms Standard Shots

The primary goal was to measure how well the modRNA ...